Long-Term Immunogenicity and Safety of a Homologous Third Dose Booster Vaccination with TURKOVAC: Phase 2 Clinical Study Findings with 32-Week Post-Booster Follow-Up

Vaccine-induced immunity wanes over time and warrants booster doses. We investigated the long-term (32 weeks) immunogenicity and safety of a third, homologous, open-label booster dose of TURKOVAC, administered 12 weeks after completion of the primary series in a randomized, controlled, double-blind,...

وصف كامل

التفاصيل البيبلوغرافية

المؤلفون الرئيسيون:	Zafer Sezer, Shaikh Terkis Islam Pavel, Ahmet Inal, Hazel Yetiskin, Busra Kaplan, Muhammet Ali Uygut, Ahmet Furkan Aslan, Adnan Bayram, Mumtaz Mazicioglu, Gamze Kalin Unuvar, Zeynep Ture Yuce, Gunsu Aydin, Refika Kamuran Kaya, Ihsan Ates, Ates Kara, Aykut Ozdarendeli
التنسيق:	Artigo
اللغة:	Inglês
منشور في:	MDPI AG 2024-01-01
سلاسل:	Vaccines
الموضوعات:	booster COVID-19 immunogenicity inactivated vaccine neutralizing antibody S1 RBD
الوصول للمادة أونلاين:	https://www.mdpi.com/2076-393X/12/2/140
الوسوم:	إضافة وسم لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!